Trial Profile

A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 4406F (Primary)
Indications Neuromyelitis optica
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Bio-Thera Solutions

Most Recent Events

14 Jan 2025 Results presented in the Bio-Thera Solutions Media Release.
26 Apr 2023 Planned number of patients changed from 48 to 15.
26 Apr 2023 Planned End Date changed from 1 Dec 2021 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com